GPR176 Is a Biomarker for Predicting Prognosis and Immune Infiltration in Stomach Adenocarcinoma

Figure 4

Expression levels of GPR176 and prediction of response to immunotherapy in LIHC. (a) In the case of both CTLA4 and PD-1 double negative, the low GPR176 cohort had higher IPS. (b) In the case of both CTLA4 and PD-1 double positive, the low GPR176 cohort had higher IPS. (c) In the case of CTLA4 negative but PD1 positive, the high GPR176 cohort had higher IPS. (d) In the case of CTLA4 positive but PD1 negative, the high GPR176 cohort had higher IPS.

(a)

(b)

(c)

(d)